Search
Galcanezumab
go.drugbank.com/drugs/DB14042ApprovedInvestigationalA pregnancy exposure registry has been established to evaluate the safety of this drug in pregnant women.[L42060] … Galcanezumab is a humanized monoclonal antibody developed by Eli Lilly and Company against human calcitonin gene-related peptide (CGRP).
Products: EMGALİTY 120 MG/ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR KALEM, 2 ADET, EMGALİTY 120 MG/ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR KALEM, 3 ADETPolidocanol
go.drugbank.com/drugs/DB06811ApprovedInvestigationalPolidocanol is a sclerosing agent indicated to treat uncomplicated spider veins (varicose veins ≤1 mm in diameter) and uncomplicated reticular veins (varicose veins 1 to 3 mm in diameter) in the lower … The formula for Polidocanol has the structural formula C12H25(OCH2CH2)nOH, a mean extent of polymerization (n) of approximately 9 and a mean molecular weight of approximately 600.
Mixtures: DENTINOX 3.4 MG/G + 3.2 MG/G + 150 MG/G JEL, 20 G, KORTOS 27 MG/5 MG SUPOZİTUVAR, 10 ADETCategories: Compounds used in a research, industrial, or household settingPimozide
go.drugbank.com/drugs/DB01100ApprovedA diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to haloperidol for the suppression of vocal and motor tics in patients with Tourette syndrome.
Categories: Heterocyclic Compounds, 2-Ring, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic IndexProducts: NOROFREN 2 MG TABLET, 20 ADET, NOROFREN 2 MG TABLET, 10 ADETSirolimus
go.drugbank.com/drugs/DB00877ApprovedInvestigational[L39267] Sirolimus was also investigated in other cancers such as skin cancer, Kaposi’s Sarcoma, cutaneous T-cell lymphomas, and tuberous sclerosis. … Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexProducts: RAPAMUNE TABLET 2 mg, RAPAMUNE ORAL SOLUTION 1 mg/mlATM-3507
go.drugbank.com/drugs/DB17198ExperimentalSynonyms: Methanone, (3-((2,3-dimethyl-1-(3-(4-methyl-1-piperazinyl)propyl)-1h-indol-5-yl)oxy)phenyl)(4-(2-(4-fluorophenyl)ethyl)-1-piperazinyl)-, (3-((2,3-dimethyl-1-(3-(4-methylpiperazin-1-yl)propyl)-1h-indol-5-yl)oxy)phenyl)(4-(4-fluorophenethyl)piperazin-1-yl)methanoneJS-K
go.drugbank.com/drugs/DB17257ExperimentalSynonyms: 1-piperazinecarboxylic acid, 4-(2-(2,4-dinitrophenoxy)-1-oxidodiazenyl)-, ethyl ester, O2-(2,4-dinitrophenyl) 1-((4-ethoxycarbonyl)piperazin-1-yl)diazen-1-ium-1,2-diolatePrucalopride
go.drugbank.com/drugs/DB06480ApprovedInvestigationalPrucalopride is a dihydrobenzofurancarboxamide derivative from the benzofurane family that selectively stimulates 5-HT4 receptors and thus, it presents enterokinetic properties. … [A40254] Prucalopride was developed by Shire Development LLC and approved for use in Europe in 2009,[A40250] in Canada on December 7, 2011 and by the FDA on December 17, 2018.[L4880]
Categories: Heterocyclic Compounds, 2-Ring, Cytochrome P-450 SubstratesProducts: Resolor Film-coated Tablet 2 mg, RESOLOR ® TABLETAS RECUBIERTAS DE 2 MGRituximab
go.drugbank.com/drugs/DB00073ApprovedInvestigationalOn November 28, 2018, the US FDA approved _Truxima_, the first biosimilar to Rituxan (Rituximab) [L4808]. … FDA in 1997 as a single agent to treat patients with B-cell Non-Hodgkin's Lymphoma (NHL) [L4811], however, has now been approved for a variety of conditions [FDA label].
Categories: CD20 (Clusters of Differentiation 20) inhibitors, CHOP-R chemotherapy regimenProducts: NOVEX 100 MG/10 ML I.V. İNFÜZYONLUK ÇÖZELTİ İÇİN KONSANTRE, 2 FLAKON, MABTHERA 100 MG/10 ML IV INFUZYON İÇİN KONSANTRE ÇÖZELTİ İÇEREN FLAKON, 2 ADETAdalimumab
go.drugbank.com/drugs/DB00051ApprovedInvestigationalA high-concentration, citrate-free formulation of Cyltezo® (adalimumab-adbm), a biosimilar to Humira®, was approved by the FDA in May 2024 for the treatment of multiple chronic inflammatory diseases. … A biosimilar marketed as Hyrimoz, a high-concentration formulation of adalimumab, is also available.[L45643,L45818].
Products: HUMİRA 20 MG/0,2 ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR ENJEKTÖR, 2 ADET, HYRİMOZ 40 MG/0,8 ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR KALEM, 2 ADETTacrolimus
go.drugbank.com/drugs/DB00864ApprovedInvestigationalThis FKBP12-FK506 complex inhibits calcineurin which inhibits T-lymphocyte signal transduction and IL-2 transcription. … It reduces peptidyl-prolyl isomerase activity by binding to the immunophilin FKBP-12 (FK506 binding protein) creating a new complex.
Mixtures: Hyaluronic Acid Sodium Salt 1% / Tacrolimus 0.1% / Urea 20%, Hyaluronic Acid Sodium Salt 1% / Niacinamide 4% / Tacrolimus 0.1%Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index